161 related articles for article (PubMed ID: 30358016)
21. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
22. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
23. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents.
Fernández-Ruiz M; García-Ríos E; Redondo N; Rodríguez-Goncer I; Ruiz-Merlo T; Parra P; Sandonis V; López-Medrano F; San Juan R; González E; Polanco N; Andrés A; Navarro D; Aguado JM; Pérez-Romero P
J Infect Dis; 2024 Jun; 229(6):1812-1816. PubMed ID: 37740549
[TBL] [Abstract][Full Text] [Related]
24. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation.
Emery VC; Asher K; Sanjuan Cde J
J Clin Virol; 2012 Jun; 54(2):125-9. PubMed ID: 22445261
[TBL] [Abstract][Full Text] [Related]
25. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.
Camargo JF; Komanduri KV
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):233-238. PubMed ID: 28641094
[TBL] [Abstract][Full Text] [Related]
26. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
[TBL] [Abstract][Full Text] [Related]
27. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation.
Boland GJ; Hene RJ; Ververs C; de Haan MA; de Gast GC
Clin Exp Immunol; 1993 Nov; 94(2):306-12. PubMed ID: 8222321
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
30. Prediction of cytomegalovirus infection: A single-center experience utilizing a newly available cell-mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity.
Jorgenson MR; Hillis MI; Saddler CM; Smith JA; Parajuli S; Mandelbrot DA
Transpl Infect Dis; 2020 Aug; 22(4):e13311. PubMed ID: 32386076
[TBL] [Abstract][Full Text] [Related]
31. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
García-Ríos E; Nuévalos M; Mancebo FJ; Pérez-Romero P
Front Immunol; 2021; 12():657144. PubMed ID: 33968058
[TBL] [Abstract][Full Text] [Related]
32. Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients.
Imlay H; Wagener MM; Vutien P; Perkins J; Singh N; Limaye AP
Transplantation; 2023 Apr; 107(4):988-993. PubMed ID: 36173456
[TBL] [Abstract][Full Text] [Related]
33. Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation.
Royston L; Neofytos D
Curr Opin Infect Dis; 2024 Aug; 37(4):264-269. PubMed ID: 38861267
[TBL] [Abstract][Full Text] [Related]
34. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
Gardiner BJ; Nierenberg NE; Chow JK; Ruthazer R; Kent DM; Snydman DR
Clin Infect Dis; 2018 Oct; 67(9):1395-1402. PubMed ID: 29635432
[TBL] [Abstract][Full Text] [Related]
35. Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea.
La Y; Kwon DE; Yoo SG; Lee KH; Han SH; Song YG
BMC Infect Dis; 2019 Nov; 19(1):948. PubMed ID: 31703564
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
[TBL] [Abstract][Full Text] [Related]
37. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
38. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
40. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
